Skip to main content
. 2015 Jun 15;5(7):2202–2211.

Figure 3.

Figure 3

Cell viability (A) and apoptosis (B) in HCC827 and HCC827-ER assessed by MTT and apoptosis assay. (HCC827: *P > 0.05 vs Erlotinib; *P < 0.05 vs Control or VPA; HCC827-ER: †P < 0.05 vs Control or Erlotinib or VPA). (C) Expression of the MAPK, AKT and mitochondrial pathway-related proteins assessed by immunoblotting.